Logo image
Back
Management of Fibroblast Growth Factor Inhibitor Treatment–emergent Adverse Events of Interest in Patients with Locally Advanced or Metastatic Urothelial Carcinoma
Journal article   Open access   Peer reviewed

Management of Fibroblast Growth Factor Inhibitor Treatment–emergent Adverse Events of Interest in Patients with Locally Advanced or Metastatic Urothelial Carcinoma

Arlene O. Siefker-Radtke, Andrea Necchi, Se Hoon Park, Jesús García-Donas, Robert A. Huddart, Earle F. Burgess, Mark T. Fleming, Arash Rezazadeh Kalebasty, Begoña Mellado, Sergei Varlamov, …
European urology open science (Online), Vol.50, pp.1-9
04/01/2023
DOI: 10.1016/j.euros.2022.12.019
PMCID: PMC10123440
PMID: 37101768
url
https://doi.org/10.1016/j.euros.2022.12.019View
Published (Version of record) Open Access

Abstract

Identification of select treatment-emergent adverse events (TEAEs) and appropriate management with dose modification and concomitant therapies result in the resolution of the majority of TEAEs. This may prevent treatment discontinuation, ensuring maximum benefit with erdafitinib. Erdafitinib is indicated for the treatment of adults with locally advanced/metastatic urothelial carcinoma and susceptible FGFR3/2 alterations progressing on/after one or more lines of prior platinum-based chemotherapy. To better understand the frequency and management of select treatment-emergent adverse events (TEAEs) to enable optimal fibroblast growth factor receptor inhibitor (FGFRi) treatment. Longer-term efficacy and safety results of the BLC2001 (NCT02365597) trial in patients with locally advanced and unresectable or metastatic urothelial carcinoma were studied. Erdafitinib schedule of 8 mg/d continuous in 28-d cycles, with uptitration to 9 mg/d if serum phosphate level was <5.5 mg/dl and no significant TEAEs occurred. Adverse events were graded using National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0. The Kaplan-Meier methodology was used for the cumulative incidence of the first onset of TEAEs by grade. Time to resolution of TEAEs was summarized descriptively. At data cutoff, the median treatment duration was 5.4 mo among 101 patients receiving erdafitinib. Select TEAEs (total; grade 3) were hyperphosphatemia (78%; 2.0%), stomatitis (59%; 14%), nail events (59%; 15%), non–central serous retinopathy (non-CSR) eye disorders (56%; 5.0%), skin events (55%; 7.9%), diarrhea (55%; 4.0%), and CSR (27%; 4.0%). Select TEAEs were mostly of grade 1 or 2, and were managed effectively with dose modifications, including dose reductions or interruptions, and/or supportive concomitant therapies, resulting in few events leading to treatment discontinuation. Further work is needed to determine whether management is generalizable to the nonprotocol/general population. Identification of select TEAEs and appropriate management with dose modification and/or concomitant therapies resulted in improvement or resolution of most TEAEs in patients, allowing for continuation of FGFRi treatment to ensure maximum benefit. Early identification and proactive management are warranted to mitigate or possibly prevent erdafitinib side effects to allow for maximum drug benefit in patients with locally advanced or metastatic bladder cancer.
 Erdafitinib Fibroblast growth factor inhibitor Toxicity Urothelial carcinoma

Details

Metrics

7 Record Views
8 Times Cited - Web of Science
Logo image